citalopram has been researched along with Hot Flashes in 29 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Hot Flashes: A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen." | 9.69 | Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| "The goal of the current study was to evaluate the efficiency of a phytotherapeutic intervention consisting of a combination of Nigella sativa and Vitex agnus-castus with citalopram in the control of hot flashes in healthy menopausal women." | 9.30 | Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. ( Afshar, S; Amin, G; Darvishi, B; Jafari Azar, Z; Molaie, M; Shirazi, M, 2019) |
| "Recurrence of VMS (frequency, severity, and bother) was measured with daily diaries for 3 weeks after cessation of escitalopram, which was administered to perimenopausal/postmenopausal women with hot flashes and night sweats in an 8-week randomized, placebo-controlled trial." | 9.17 | Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. ( Carpenter, JS; Cohen, LS; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Larson, J, 2013) |
| "The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes." | 9.16 | Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. ( Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Landis, CA; Larson, JC; Newton, KM; Reed, SD; Sternfeld, B; Woods, NF, 2012) |
| "To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes." | 9.16 | Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. ( Carpenter, JS; Cohen, L; Ensrud, KE; Freeman, EW; Joffe, H; LaCroix, AZ; Larson, J; Newton, KM; Reed, SD; Seguin, RA; Sternfeld, B, 2012) |
| "To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flashes." | 9.15 | Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. ( Anderson, GL; Caan, B; Carpenter, JS; Cohen, LS; Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; LaCroix, AZ; Larson, JC; Newton, KM; Reed, SD; Sammel, MD; Sherman, S; Sternfeld, B, 2011) |
| "The aim of this study was to determine the effects of 10 and 20 mg/day of escitalopram on objectively recorded hot flashes and on the rectal temperature threshold for sweating." | 9.15 | Escitalopram treatment of menopausal hot flashes. ( Freedman, RR; Kruger, ML; Tancer, ME, 2011) |
| " Data for hot flash scores and frequencies showed significant improvement in hot flashes with citalopram over placebo, with no significant differences among doses." | 9.14 | Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. ( Atherton, PJ; Barton, DL; Diekmann, B; Dyar, M; Flynn, KA; Johnson, DB; LaVasseur, BI; Loprinzi, CL; Sloan, JA; Stawis, AN, 2010) |
| "The objective of this trial was to provide pilot information with regards to whether citalopram would effectively reduce hot flashes in patients who did not receive adequate enough hot flash reduction with venlafaxine." | 9.11 | Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. ( Adjei, AA; Atherton, P; Barton, DL; Carpenter, LA; Collins, M; Fitch, TR; Flynn, PJ; Loprinzi, CL; Mincey, BA; Rummans, TA; Shanafelt, TD; Sloan, JA, 2005) |
| "We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen." | 5.69 | Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| "The goal of the current study was to evaluate the efficiency of a phytotherapeutic intervention consisting of a combination of Nigella sativa and Vitex agnus-castus with citalopram in the control of hot flashes in healthy menopausal women." | 5.30 | Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. ( Afshar, S; Amin, G; Darvishi, B; Jafari Azar, Z; Molaie, M; Shirazi, M, 2019) |
| "Citalopram and venlafaxine are equally more effective than placebo in reducing sleep disturbance and severity of hot flashes, while citalopram is more effective in reducing frequency of hot flashes than venlafaxine." | 5.22 | Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. ( Asadi, M; Davari-Tanha, F; Hadizadeh, H; Shariat, M; Shirazi, M; Soleymani-Farsani, M, 2016) |
| "Recurrence of VMS (frequency, severity, and bother) was measured with daily diaries for 3 weeks after cessation of escitalopram, which was administered to perimenopausal/postmenopausal women with hot flashes and night sweats in an 8-week randomized, placebo-controlled trial." | 5.17 | Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. ( Carpenter, JS; Cohen, LS; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Larson, J, 2013) |
| "The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes." | 5.16 | Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. ( Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Landis, CA; Larson, JC; Newton, KM; Reed, SD; Sternfeld, B; Woods, NF, 2012) |
| "To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flashes." | 5.15 | Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. ( Anderson, GL; Caan, B; Carpenter, JS; Cohen, LS; Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; LaCroix, AZ; Larson, JC; Newton, KM; Reed, SD; Sammel, MD; Sherman, S; Sternfeld, B, 2011) |
| "The aim of this study was to determine the effects of 10 and 20 mg/day of escitalopram on objectively recorded hot flashes and on the rectal temperature threshold for sweating." | 5.15 | Escitalopram treatment of menopausal hot flashes. ( Freedman, RR; Kruger, ML; Tancer, ME, 2011) |
| "The objective of this trial was to provide pilot information with regards to whether citalopram would effectively reduce hot flashes in patients who did not receive adequate enough hot flash reduction with venlafaxine." | 5.11 | Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. ( Adjei, AA; Atherton, P; Barton, DL; Carpenter, LA; Collins, M; Fitch, TR; Flynn, PJ; Loprinzi, CL; Mincey, BA; Rummans, TA; Shanafelt, TD; Sloan, JA, 2005) |
| "Results from these trials indicate that paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine are effective in reducing the frequency and severity of hot flashes." | 4.91 | The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. ( Handley, AP; Williams, M, 2015) |
| "Significant improvements in total Menopause-specific Quality of Life from baseline were observed with estradiol, escitalopram, CBT-I, and yoga, with mean decreases of 0." | 3.96 | Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials. ( Diem, SJ; Ensrud, KE; Guthrie, KA; LaCroix, AZ; Larson, JC; Newton, KM; Reed, SD; Woods, NF, 2020) |
| "Omega-3 supplements did not improve insomnia symptoms." | 2.87 | Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. ( Anderson, GL; Carpenter, JS; Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; LaCroix, AZ; Larson, JC; Manson, JE; McCurry, SM; Morin, CM; Newton, KM; Otte, J; Reed, SD, 2018) |
| "Hot flashes are very common in women in menopause and can have a detrimental effect on quality of life." | 2.49 | New generation nonhormonal management for hot flashes. ( Ichigo, S; Imai, A; Matsunami, K; Takagi, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 24 (82.76) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Taleghani, SY | 1 |
| Etesam, F | 1 |
| Esfandbod, M | 1 |
| Diem, SJ | 1 |
| LaCroix, AZ | 9 |
| Reed, SD | 9 |
| Larson, JC | 7 |
| Newton, KM | 7 |
| Ensrud, KE | 8 |
| Woods, NF | 2 |
| Guthrie, KA | 9 |
| Anderson, GL | 4 |
| Carpenter, JS | 7 |
| Freeman, EW | 9 |
| Joffe, H | 9 |
| Manson, JE | 2 |
| Morin, CM | 1 |
| Otte, J | 1 |
| McCurry, SM | 1 |
| Lyon, C | 1 |
| Mullen, R | 1 |
| Deffenbacher, B | 1 |
| Reed, A | 1 |
| Nashelsky, J | 1 |
| Molaie, M | 1 |
| Darvishi, B | 1 |
| Jafari Azar, Z | 1 |
| Shirazi, M | 2 |
| Amin, G | 1 |
| Afshar, S | 1 |
| Loprinzi, C | 1 |
| Bostwick, JM | 1 |
| Larson, J | 2 |
| Cohen, LS | 4 |
| Caan, B | 3 |
| Sternfeld, B | 5 |
| Sherman, S | 2 |
| Sammel, MD | 2 |
| Kroenke, K | 1 |
| Handley, AP | 1 |
| Williams, M | 1 |
| Rexrode, K | 1 |
| Skaar, TC | 1 |
| Davari-Tanha, F | 1 |
| Soleymani-Farsani, M | 1 |
| Asadi, M | 1 |
| Shariat, M | 1 |
| Hadizadeh, H | 1 |
| Biglia, N | 1 |
| Bounous, VE | 1 |
| Susini, T | 1 |
| Pecchio, S | 1 |
| Sgro, LG | 1 |
| Tuninetti, V | 1 |
| Torta, R | 1 |
| Barton, DL | 2 |
| LaVasseur, BI | 1 |
| Sloan, JA | 2 |
| Stawis, AN | 1 |
| Flynn, KA | 1 |
| Dyar, M | 1 |
| Johnson, DB | 1 |
| Atherton, PJ | 1 |
| Diekmann, B | 1 |
| Loprinzi, CL | 3 |
| Freedman, RR | 1 |
| Kruger, ML | 1 |
| Tancer, ME | 1 |
| Appiani, F | 1 |
| Carroll, BT | 1 |
| Muñoz, C | 1 |
| Trecco, J | 1 |
| Shifren, JL | 1 |
| Seguin, RA | 2 |
| Landis, CA | 1 |
| Santoro, N | 1 |
| Imai, A | 1 |
| Matsunami, K | 1 |
| Takagi, H | 1 |
| Ichigo, S | 1 |
| Pachman, DR | 1 |
| Morgenthaler, TI | 1 |
| Cohen, L | 1 |
| Bezerra, AG | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Hachul, H | 1 |
| Flynn, PJ | 1 |
| Carpenter, LA | 1 |
| Atherton, P | 1 |
| Shanafelt, TD | 1 |
| Rummans, TA | 1 |
| Adjei, AA | 1 |
| Mincey, BA | 1 |
| Fitch, TR | 1 |
| Collins, M | 1 |
| Albertazzi, P | 1 |
| Alexander, IM | 1 |
| Moore, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Menopausal Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) 04: A Pilot Trial of Telephone-Based Cognitive-Behavioral Therapy for Midlife Women With Menopause-related Sleep Disturbance[NCT01936441] | 106 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women[NCT00894543] | 205 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation[NCT01178892] | 355 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms[NCT01418209] | 339 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes[NCT00363909] | Phase 3 | 254 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease[NCT03977441] | Phase 4 | 240 participants (Anticipated) | Interventional | 2019-07-31 | Not yet recruiting | ||
| Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.[NCT02040532] | 32 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in daily hot flash frequency was calculated as the daily mean difference between baseline and week 4. Baseline was calculated as the daily mean of the daily frequencies for the first two screening weeks. Week 4 was calculated as the daily mean of the daily frequencies during the week prior to the week 4 visit. (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | -4.37 |
| Placebo | -2.49 |
Change in daily hot flash frequency was calculated as the daily mean difference between baseline and week 8. Baseline was calculated as the daily mean of the frequencies for the first two screening weeks. Week 8 was calculated as the daily mean of the daily frequencies during the week prior to the week 8 visit. (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | -4.60 |
| Placebo | -3.20 |
"Change in daily hot flash bother was calculated as the mean difference between baseline and week 4. Baseline was calculated as the daily mean of the highest daily bother ratings during the first two screening weeks. Week 4 was calculated as the daily mean of the highest of the daily bother ratings during the week prior to the week 4 visit.~Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), or 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.59 |
| Placebo | -0.29 |
"Change in daily hot flash severity from baseline to week 4 was calculated as the mean difference in hot flash severity ratings between baseline and week 4. Baseline was calculated as the daily mean from the first two weeks of hot flash severity ratings. Week 4 severity ratings were calculated as the daily mean from the ratings for the week prior to the week 4 visit.~Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.43 |
| Placebo | -0.23 |
Change in daily hot flash severity between baseline & week 8 was calculated as mean difference. Baseline severity ratings were calculated as daily mean ratings for the first two screening weeks pre-baseline. Week 8 severity ratings were calculated as daily mean ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN). (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.53 |
| Placebo | -0.30 |
Baseline hot flash frequency per day was calculated as the daily mean of the daily totals reported during the first two screening weeks. (NCT00894543)
Timeframe: Baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | 9.88 |
| Placebo | 9.66 |
"Daily Hot flash bother scores were calculated by selecting the highest bother rating for hot flashes or night sweats for each woman in each 24-hour day. The score was set to missing on on any day data were missing or or hot flashes equaled 0. The daily mean of daily ratings for the first 2 screening weeks is reported.~Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), or 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | 3.12 |
| Placebo | 3.16 |
"Daily hot flash severity scores were calculated by by selecting the highest severity rating for hot flashes or night sweats for each woman in each 24-hour day. The score was set to missing on on any day data were missing or or hot flashes equaled 0. The daily mean of daily ratings for the first 2 screening weeks is reported.~Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | 2.16 |
| Placebo | 2.19 |
Change in daily hot flash bother between baseline & week 8 was calculated as mean difference. Baseline daily bother was the mean of the highest daily ratings for two screening weeks pre-baseline. Week 8 bother was daily mean of the highest daily bother ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN). (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.63 |
| Placebo | -0.39 |
Measured by self-report diary twice daily (day and night) for 7 days. Bothersomeness ratings ranged from 0 to 3 with lower numbers being less bothersome and higher numbers being more bothersome. Data from the day and night bothersomeness ratings were averaged for a single daily score. The single daily scores for the week prior to the week 4 study assessment were summed and averaged to produce a mean daily VMS bothersomeness for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 1.6 |
| Venlafaxine XR | 1.6 |
| Placebo | 1.7 |
Measured by self-report diary twice daily (day and night) for 7 days. Bothersomeness ratings ranged from 0 to 3 with lower numbers being less bothersome and higher numbers being more bothersome. Data from the day and night bothersomeness ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS bothersomeness for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 1.4 |
| Venlafaxine XR | 1.4 |
| Placebo | 1.6 |
Measured by self-report diary twice daily (day and night). The day and night frequencies were summed to produce a single number of hot flashes per day. The single number of hot flashes per day were summed and averaged for one week prior to the week 8 study assessment to produce a mean daily frequency for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | number of hot flashes per day (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 3.9 |
| Venlafaxine XR | 4.4 |
| Placebo | 5.5 |
Measured by self-report diary twice daily (day and night). The day and night frequencies were summed to produce a single number of hot flashes per day. The single number of hot flashes per day were summed and averaged for one week prior to the week 4 study assessment to produce a mean daily frequency for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | number of hot flashes per day (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 5.3 |
| Venlafaxine XR | 5.1 |
| Placebo | 5.8 |
The perceived hot flash related daily interference scale (HFRDIS) is a tool for assessing the impact of hot flashes on quality of life. There are 10 questions with each having a score ranging from 0 to 10. The scores from each question are summed for a total score ranging from 0 to 100. Lower numbers indicate less interference and higher numbers indicate more interference. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 18.3 |
| Venlafaxine XR | 19.8 |
| Placebo | 24.2 |
The perceived hot flash related daily interference scale (HFRDIS) is a tool for assessing the impact of hot flashes on quality of life. There are 10 questions with each having a score ranging from 0 to 10. The scores from each question are summed for a total score ranging from 0 to 100. Lower numbers indicate less interference and higher numbers indicate more interference. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 14.6 |
| Venlafaxine XR | 18.3 |
| Placebo | 21.5 |
Measured by self-report diary twice daily (day and night) for 7 days. Severity ratings ranged from 0 to 3 with lower numbers being less severe and higher numbers being more severe. Data from the day and night severity ratings were averaged for a single daily score. The single daily scores for the week prior to the week 4 study assessment were summed and averaged to produce a mean daily VMS severity for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 0.7 |
| Venlafaxine XR | 0.7 |
| Placebo | 0.8 |
Measured by self-report diary twice daily (day and night) for 7 days. Severity ratings ranged from 0 to 3 with lower numbers being less severe and higher numbers being more severe. Data from the day and night severity ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS severity for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 0.6 |
| Venlafaxine XR | 0.6 |
| Placebo | 0.7 |
"The Quality of life-Menopause specific is assessed by the Menopause Specific Quality of Life (MENQOL).~The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a zero (not bothersome) to six (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a 1 and endorsement a 2, plus the number of the particular rating, so that the possible score on any item ranges from 1-8. Total score also ranges from 1-8." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| MENQOL scores at baseline | MENQOL scores at study completion | |
| Open-label Gabapentin | 3.2 | 1.9 |
Quality of life-Overall was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The Q-LES-Q is a 16-item self-report questionnaire that assesses enjoyment of and satisfaction with life. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70 with higher scores indicating higher quality of life enjoyment and satisfaction. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Q-LES-Q scores at baseline | Q-LES-Q scores at study completion | |
| Open-label Gabapentin | 60.3 | 61.7 |
"Severity of insomnia was measured throughout the study using the Insomnia Severity Index (ISI) .The ISI is a 7-item scale that evaluates the severity of insomnia retrospectively over the past week. The scale is more specific to insomnia symptoms than the Pittsburgh scale (PSQI), which focuses more broadly on overall sleep quality.~The ISI score ranges from a minimum of 0 to 28. A score of 0-7=no clinically significant insomnia, 8-14=subthreshold insomnia, 5-21=clinical insomnia (moderate severity), 22-28=clinical insomnia (severe), with higher values indicating more severe insomnia." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| mean ISI score at baseline | mean ISI score at study completion | |
| Open-label Gabapentin | 15.6 | 6.0 |
"Sleep quality and disturbances during the past month were assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI also incorporates daytime functioning into the total score.~In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| PSQI total score at baseline | PSQI total score at study completion | |
| Open-label Gabapentin | 9.6 | 4.9 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per day (Mean) | |
|---|---|---|
| mean VMS per day at baseline | mean VMS per day at study completion | |
| Open-label Gabapentin | 4.1 | 2.2 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per night (Mean) | |
|---|---|---|
| mean VMS per night at baseline | mean VMS per night at study completion | |
| Open-label Gabapentin | 3.5 | 1.1 |
5 reviews available for citalopram and Hot Flashes
| Article | Year |
|---|---|
Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms?
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Estrogen Replacement Therapy; Exercise T | 2018 |
The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Topics: Adult; Aged; Citalopram; Desvenlafaxine Succinate; Female; Fluoxetine; Hot Flashes; Humans; Menopaus | 2015 |
New generation nonhormonal management for hot flashes.
Topics: Amines; Anticonvulsants; Citalopram; Cyclohexanecarboxylic Acids; Estrogen Replacement Therapy; Fema | 2013 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapin | 2006 |
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclo | 2007 |
15 trials available for citalopram and Hot Flashes
| Article | Year |
|---|---|
Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer.
Topics: Adult; Aged; Breast Neoplasms; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopau | 2023 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Double-Blind Met | 2018 |
Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis.
Topics: Adult; Citalopram; Double-Blind Method; Drug Therapy, Combination; Female; Hot Flashes; Humans; Meno | 2019 |
Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Topics: Adult; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Perimen | 2013 |
Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Topics: Adult; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Perimen | 2013 |
Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Topics: Adult; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Perimen | 2013 |
Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Topics: Adult; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Perimen | 2013 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
Topics: Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; Estrogens; Exercise; | 2015 |
Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.
Topics: Citalopram; Depression; Double-Blind Method; Female; Hot Flashes; Humans; Iran; Middle Aged; Postmen | 2016 |
Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agent | 2018 |
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
Topics: Antineoplastic Agents, Hormonal; Citalopram; Double-Blind Method; Drug Administration Schedule; Fema | 2010 |
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
Topics: Antineoplastic Agents, Hormonal; Citalopram; Double-Blind Method; Drug Administration Schedule; Fema | 2010 |
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
Topics: Antineoplastic Agents, Hormonal; Citalopram; Double-Blind Method; Drug Administration Schedule; Fema | 2010 |
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
Topics: Antineoplastic Agents, Hormonal; Citalopram; Double-Blind Method; Drug Administration Schedule; Fema | 2010 |
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Topics: Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; | 2011 |
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Topics: Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; | 2011 |
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Topics: Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; | 2011 |
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Topics: Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; | 2011 |
Escitalopram treatment of menopausal hot flashes.
Topics: Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2011 |
Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial.
Topics: Adult; Citalopram; Female; Hot Flashes; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Black or African American; Citalopram; Double-Blind Method; Female; Hot Flashes; Humans; Meno | 2012 |
Effect of escitalopram on hot flash interference: a randomized, controlled trial.
Topics: Adult; Affect; Circadian Rhythm; Citalopram; Female; Follow-Up Studies; Hot Flashes; Humans; Menopau | 2012 |
Effect of escitalopram on hot flash interference: a randomized, controlled trial.
Topics: Adult; Affect; Circadian Rhythm; Citalopram; Female; Follow-Up Studies; Hot Flashes; Humans; Menopau | 2012 |
Effect of escitalopram on hot flash interference: a randomized, controlled trial.
Topics: Adult; Affect; Circadian Rhythm; Citalopram; Female; Follow-Up Studies; Hot Flashes; Humans; Menopau | 2012 |
Effect of escitalopram on hot flash interference: a randomized, controlled trial.
Topics: Adult; Affect; Circadian Rhythm; Citalopram; Female; Follow-Up Studies; Hot Flashes; Humans; Menopau | 2012 |
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Citalopram; Cohort Studies; Double-Blind Method; Female; Hot Flashes; Humans; Linear Models; | 2012 |
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Citalopram; Cohort Studies; Double-Blind Method; Female; Hot Flashes; Humans; Linear Models; | 2012 |
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Citalopram; Cohort Studies; Double-Blind Method; Female; Hot Flashes; Humans; Linear Models; | 2012 |
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Topics: Adult; Citalopram; Cohort Studies; Double-Blind Method; Female; Hot Flashes; Humans; Linear Models; | 2012 |
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.
Topics: Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Female; Hot Flashes; Humans; Middle Aged; | 2005 |
9 other studies available for citalopram and Hot Flashes
| Article | Year |
|---|---|
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Quality of Life; Yoga | 2020 |
Extinguishing hot flash therapy.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors; Sweatin | 2013 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Topics: Biomedical Research; Citalopram; Cyclohexanols; Dietary Supplements; Double-Blind Method; Estradiol; | 2014 |
The antidepressant citalopram cuts hot flash severity and frequency.
Topics: Citalopram; Controlled Clinical Trials as Topic; Female; Health Knowledge, Attitudes, Practice; Hot | 2010 |
Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Citalopram; Cytochrome P-450 | 2011 |
Antidepressant may help ease hot flashes.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Double-Blind | 2011 |
Running interference.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors | 2012 |
Hot flashes and antidepressant agents: uneasy bedfellows.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors; Sleep; | 2012 |
Approach towards mild depression: shortest way to treat climacteric syndrome?
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors | 2013 |